These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31346328)

  • 1. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy.
    Peng H; Chen R; Brentnall TA; Eng JK; Picozzi VJ; Pan S
    Clin Proteomics; 2019; 16():31. PubMed ID: 31346328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy.
    Sahni S; Nahm C; Krisp C; Molloy MP; Mehta S; Maloney S; Itchins M; Pavlakis N; Clarke S; Chan D; Gill AJ; Howell VM; Samra J; Mittal A
    Front Oncol; 2020; 10():237. PubMed ID: 32195182
    [No Abstract]   [Full Text] [Related]  

  • 3. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
    Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients.
    Peng H; Pan S; Yan Y; Brand RE; Petersen GM; Chari ST; Lai LA; Eng JK; Brentnall TA; Chen R
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival.
    Amantini C; Morelli MB; Nabissi M; Piva F; Marinelli O; Maggi F; Bianchi F; Bittoni A; Berardi R; Giampieri R; Santoni G
    Front Oncol; 2019; 9():874. PubMed ID: 31552188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.
    Sahni S; Krisp C; Molloy MP; Nahm C; Maloney S; Gillson J; Gill AJ; Samra J; Mittal A
    Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129682. PubMed ID: 32663515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
    Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
    Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
    Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
    Front Oncol; 2021; 11():708963. PubMed ID: 34290990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
    Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
    Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
    Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteome alterations in pancreatic ductal adenocarcinoma.
    Pan S; Brentnall TA; Chen R
    Cancer Lett; 2020 Jan; 469():429-436. PubMed ID: 31734355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    O'Rourke MB; Sahni S; Samra J; Mittal A; Molloy MP
    J Proteomics; 2021 Jan; 231():103998. PubMed ID: 33027703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
    Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
    Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.